Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients
Compare the effects of Narrowband Ultraviolet B versus acitretin on serum Omentin-1 level in psoriatic patients as case control study by dividing patients into 3 groups: group 1 include patients receive Narrowband Ultraviolet B, group II includes patients receive acitretin (0.5-1 mg/day) and control group. The duration of this study about 3 months after receving those interventions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NB-UVB group | Active Comparator | Patients who receive Narrowband ultraviolet B phototherapy |
|
| Acitretin group | Active Comparator | Patients who receive acitretin |
|
| Control group | No Intervention | It includes apparently healthy people who will be compared to patients in the measurement of Omentin-1 level |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Narrowband Ultraviolet B | Radiation | patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Decrease Omentin-1 serum level in both groups treated with NB-UVB and Acitretin | This outcome indicates potential role of Omentin-1 in psoriasis pathogenesis and its involvement in pathogenesis of obesity and related diseases as metabolic syndrome. So it will be concluded that high levels of this protein could be marker against obesity and related disorders including psoriasis. Omentin-1 can be valuable marker for psoriasis severity detected by its correlation with psoriasis area severity index (PASI) score and for evaluating the therapeutic outcomes | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Decrease PASI score in psoriatic patients | Decrease in PASI score in psoriatic patients after treatment with NB-UVB acitretin | 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
• Patients with history of malignancies, renal and liver diseases.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of medicine - Aswan university | Aswān | 81528 | Egypt |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jan 24, 2022 | |
| Reset | Mar 24, 2022 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jan 24, 2022 | Mar 24, 2022 |
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017255 | Acitretin |
| ID | Term |
|---|---|
| D012176 | Retinoids |
| D002338 | Carotenoids |
| D011090 | Polyenes |
| D000475 | Alkenes |
| D006839 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Acitretin | Drug | patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months |
|
| Hydrocarbons, Acyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D013729 | Terpenes |
| D010860 | Pigments, Biological |
| D001685 | Biological Factors |